Spero Therapeutics, Inc.
SPRO
$1.23
$0.000.00%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
8/4/2026
-
Globe Newswire
8/4/2026
-
MarketBeat
7/27/2026
-
Nasdaq News: Markets
7/27/2026
-
TipRanks: TheFly
7/27/2026
-
Globe Newswire
7/14/2026
-
SeekingAlpha
7/14/2026
-
Seeking Alpha - Long Ideas
7/14/2026
-
TipRanks: TheFly
7/14/2026
-
TipRanks: TheFly
7/14/2026
-
TipRanks: TheFly
7/14/2026
-
Globe Newswire
7/14/2026
-
PR Newswire
7/14/2026
-
Globe Newswire
Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M
7/13/2026
-
FierceBiotech.com - Biotech
7/9/2026
-
MarketBeat
7/8/2026
-
Globe Newswire
6/29/2026
-
Globe Newswire
6/25/2026
-
TipRanks
6/22/2026
-
TipRanks
6/18/2026
-
Seeking Alpha - Healthcare
6/18/2026
-
Seeking Alpha - Long Ideas
6/18/2026
-
Zacks Investment Research
6/17/2026
-
TipRanks: TheFly
6/17/2026
-
Business Wire
6/17/2026
-
Globe Newswire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 13, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 242 1600
Address
675 Massachusetts Avenue
14th Floor
Cambridge, MA 02139
14th Floor
Cambridge, MA 02139
Country
Year Founded
Business Description
Sector
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases...
more